MichaelSGordonMD

Genitourinary Oncology, Gynecologic Cancer, Hematologic Oncology, Melanoma

Chief Medical Officer at HonorHealth Research Institute Medical Director, Oncology Clinical Trials at HonorHealth Research Institute

Join to view full profile

Dr. Gordon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gordon's full profile

Already have an account?

Office
10510 N 92nd Street Suite 200
Scottsdale, AZ 85258
Phone+1 480-323-1350
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
University of ChicagoResidency, Internal Medicine, 1985 - 1988
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1985
Sophie Davis School for Biomedical Education at CCNYBS, Biomedical Science, 1979 - 1983

Certifications & Licensure

AZ State Medical License 2000 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
Unknown status
Phase 1
Safety and Efficacy Study of Glufosfamide in Ovarian Cancer Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors Start of enrollment: 2008 Jan 01
Terminated
Phase 1
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies Start of enrollment: 2017 Dec 01
Completed
Phase 1
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Start of enrollment: 2019 Apr 01
Recruiting
Phase 1
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC Start of enrollment: 2019 Jul 02
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Antonio Jimeno, Joaquina Baranda, Wade T Iams, Jong Chul Park, Monica Mita, Michael S Gordon, Matthew Taylor, Neesha Dhani, Alexis D Leal, Prakash Neupane, Cathy Eng, ...> ;Investigational New Drugs. 2023 Apr 1
10 citations
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors.
Anthony W Tolcher, Michael Gordon, Kathleen M Mahoney, Anna Seto, Marianna Zavodovskaya, Chia-Hsiang Hsueh, Shuyan Zhai, Thomas Tarnowski, Juliane M Jürgensmeier, Susa...> ;Journal for Immunotherapy of Cancer. 2023 Feb 1
1 citations
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
James Larkin, Mototsugu Oya, Marcella Martignoni, Fiona Thistlethwaite, Paul Nathan, Moshe C Ornstein, Thomas Powles, Kathryn E Beckermann, Arjun V Balar, David McDerm...> ;The Oncologist. 2023 Apr 6
Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Kevin Drenner, Gargi D Basu, Laurie J Goodman, Audrey A Ozols, Janine R LoBello, Thomas Royce, Michael S Gordon, Erkut H Borazanci, Margaux A Steinbach, Jeffrey Trent,...> ;Oncotarget. 2022 Oct 20
11 citations
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Kim, T., Burris, H., de Miguel Luken, M., Pishvaian, M., Bang, Y., Gordon, M., Awada, A., Camidge, D., Hodi, F., McArthur, G., Miller, W., Cervantes, A., Chow, L., Les...> ;Clinical Cancer Research. 2022 Aug 15
15 citations
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastati...
Corinne Maurice-Dror, Ronan Le Moigne, Ulka N. Vaishampayan, Robert B. Montgomery, Michael S. Gordon, Nan Hyung Hong, Leah DiMascio, Frank Perabo, Kim N. Chi> ;Investigational New Drugs. 2021 Nov 29
13 citations
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
Joël Guigay, Keun Wook Lee, Manish R. Patel, Amaury Daste, Deborah J. Wong, Sanjay Goel, Michael S. Gordon, Martin Gutierrez, Ani Sarkis Balmanoukian, Christophe Le To...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Kevin Drenner, Gargi D. Basu, Laurie J. Goodman, Audrey A. Ozols, Janine LoBello, Thomas Royce, Michael S. Gordon, Erkut Borazanci, Margaux Steinbach, Jeffrey M. Trent...> ;Oncotarget. 2021 Aug 31
55 citations
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
Michael D. Farwell, Raymond F Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn, Alessandro Mascioni, William Le, Ian D. Wilson, Michael S. Gord...> ;Journal of Nuclear Medicine. 2021 Aug 19
19 citations
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
Suzanne George, Ping Chi, Michael Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, Jonathan C. Trent, Hans Gelderblom, Albiruni Ryan Abdul Razak, Mich...> ;European Journal of Cancer. 2021 Aug 12
3 citations
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Michael S. Gordon, John Nemunaitis, Minal A. Barve, Zev A. Wainberg, Erika Hamilton, Ramesh K. Ramanathan, George W. Sledge, Huibin Yue, Susan E. Morgan-Lappe, Martha ...> ;Molecular Cancer Therapeutics. 2021 Jul 26
6 citations
Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.
Deborah J. Wong, Todd M. Bauer, Michael S. Gordon, Fabiola Bene-Tchaleu, Jing Zhu, Xiaosong Zhang, Edward Cha> ;Clinical Lung Cancer. 2021 Jul 20
5 citations
Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Michael S Gordon, Geoffrey I Shapiro, John Sarantopoulos, Dejan Juric, Brian Lu, Angeliki Zarotiadou, Jamie N Connarn, Yvan Le Bruchec, Calin Dan Dumitru, R Donald Harvey> ;Frontiers in Oncology. 2021 Jan 1
42 citations
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael D. Gordon, Leonel Hernandez-Aya, Donald P. Lawrence, Jose Lutzky, Wilson H....> ;Nature Communications. 2020 Dec 7
29 citations
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal ...
Gary Middleton, Yiqun Yang, Catarina D. Campbell, Thierry André, Chloe E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn...> ;Clinical Cancer Research. 2020 Feb 11
24 citations
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
Robin L. Jones, Mark J. Ratain, Peter J. O'Dwyer, Lillian L. Siu, Jacek Jassem, Jacques Medioni, Maja DeJonge, Charles M. Rudin, Michael B. Sawyer, David Khayat, Ahmad...> ;European Journal of Cancer. 2019 Oct 1
47 citations
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Antonio Jimeno, Kathleen N. Moore, Michael S. Gordon, Rashmi Chugh, Jennifer R. Diamond, Raid Aljumaily, David S. Mendelson, Ann M. Kapoun, Lu Xu, Robert Joseph Stagg,...> ;Investigational New Drugs. 2019 Jun 1
22 citations
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases
Hani M. Babiker, Sara A. Byron, William P.D. Hendricks, William F. Elmquist, Gautham Gampa, Jessica Vondrak, Jessica Aldrich, Lori Cuyugan, Jonathan Adkins, Valerie De...> ;Investigational New Drugs. 2019 Aug 15
11 citations
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Noelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R. Infante, Jason C. Chandler, Andrew Weickhardt, Jason D. Lickliter, John Sarantopoulos, Michael S. Gordon, Gabriel Mak,...> ;British Journal of Clinical Pharmacology. 2018 Apr 1
350 citations
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
Ryan B. Corcoran, Thierry André, Chloe E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Gary...> ;Cancer Discovery. 2018 Apr 1
406 citations
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel, John Allan Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael Gordon, Raid Aljumaily, Carolyn D. Britten, Luc Dirix, Keun Wook Lee, Mathew Taylor, ...> ;The Lancet. Oncology. 2018 Jan 1
15 citations
Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders
Rachel N. Grisham, Kathleen N. Moore, Michael S. Gordon, Wael A. Harb, Gwendolyn R. Cody, Darragh Halpenny, Vicky Makker, Carol Aghajanian> ;Clinical Cancer Research. 2018 Jan 1
122 citations
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
Antonio Jimeno, Michael S. Gordon, Rashmi Chugh, Wells A. Messersmith, David S. Mendelson, Jakob Dupont, Robert Joseph Stagg, Ann M. Kapoun, Lu Xu, Shailaja Uttamsingh...> ;Clinical Cancer Research. 2017 Dec 15
55 citations
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Patrick Schöffski, Michael S. Gordon, David Smith, Razelle Kurzrock, Adil Daud, Nicholas J. Vogelzang, Yihua Lee, Christian Scheffold, Geoffrey I. Shapiro> ;European Journal of Cancer. 2017 Nov 1
192 citations
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and ...
Harpreet Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Ri...> ;The Lancet. Oncology. 2017 Sep 1
Join now to see all

Journal Articles

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma
Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer
E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases
Mitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs

Lectures

A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) w...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

TGen Partners with a Phoenix-Area Hospital System to Test COVID-19 TreatmentMay 5th, 2020
Advances in Cancer TreatmentSeptember 29th, 2017
Arizona Cancer Center Faces Crowded Cancer-Care MarketSeptember 2nd, 2015